Treatment
Adalimumab clinical trials
We’re tracking 34 recruiting studies that include Adalimumab, each written for real people, not researchers, below.
Recruiting studies
- NCT05590416Recruiting
Adalimumab for early Vogt-Koyanagi-Harada eye inflammation
This trial studies adalimumab to treat a rare, fast-onset eye inflammation called Vogt-Koyanagi-Harada disease. It may help people who can’t use strong steroid treatments or whose disease is not improving quickly with them.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT06180382RecruitingPhase 4
Comparing vedolizumab to higher-dose adalimumab for Crohn's disease
This trial tests whether switching to vedolizumab works better than increasing your adalimumab dose if your Crohn's symptoms or inflammation are coming back despite treatment. It aims to find the best next step for people whose condition is no longer well-controlled.
Le Kremlin-Bicêtre, PARISAges 18 years+ - NCT02706704RecruitingPhase 2
Adalimumab eye injections vs under-skin shots for uveitis
This trial compares two forms of the same medicine (adalimumab) to treat non-infectious uveitis, an inflammation inside the eye. It aims to see which delivery method works better to control active inflammation and protect vision.
BeirutAges 18 years+ - NCT07061574RecruitingPhase 1/Phase 2
Study of immune-modulating drugs for new-onset type 1 diabetes
This study tests two different medications (Anti-Thymocyte Globulin and Adalimumab or Verapamil) to see if they can slow down the loss of insulin production in people with newly diagnosed type 1 diabetes. Participants will be randomly assigned to receive one of the treatments and will be followed for about a year to see how well their bodies still make insulin.
San Francisco, CaliforniaAges 9–20 - NCT06045754RecruitingPhase 4
Study of vedolizumab with other drugs for Crohn's disease
This trial tests whether combining vedolizumab with adalimumab or ustekinumab helps people with moderate to severe Crohn's disease who haven't responded to other treatments. It aims to find better ways to manage symptoms and improve quality of life.
Dothan, AlabamaAges 18–70 - NCT07663331RecruitingPhase 4
Adalimumab for adults with non-infectious uveitis
This study tests an injection called adalimumab (Tebiovio®) to see if it helps control inflammation in the eyes of adults with non-infectious uveitis. It might be a good option if you are already on steroid pills and looking for another treatment.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06100744RecruitingPhase 3
Comparing two drugs for children with psoriatic arthritis
This study tests two drugs—risankizumab and adalimumab—to see which is safer and works better for children with active psoriatic arthritis. It's for kids who have not been helped enough by standard disease-modifying drugs.
Little Rock, ArkansasAges 5–17 - NCT03938701RecruitingPhase 2
Imaging gut and joint inflammation with adalimumab and a light tracer
This study uses a special “light tracer” medicine with adalimumab to see where inflammation is in the gut (IBD) or joints (RA). If you have active disease, it may help doctors better target treatment by showing inflammation more clearly during scans.
Groningen, Provincie GroningenAges 18 years+ - NCT04183608RecruitingPhase 4
Telemonitoring and education to guide treatment for ulcerative colitis
This trial tests whether “treat-to-target” care—guided by regular symptom checks, telemonitoring, and patient education—works better than standard follow-up when starting adalimumab for ulcerative colitis. It aims to help control inflammation more effectively and reduce flare-ups.
Cholet, Maine Et LoireAges 18–75 - NCT04300686RecruitingPhase 4
Pilot study for severe Takayasu artery inflammation
This trial studies treatment options for people age 14 and older with severe, active Takayasu arteritis causing major circulation problems and organ strain. It may help reduce inflammation and complications when the disease is flaring and difficult to control.
Shanghai, Shanghai MunicipalityAges 14–100 - NCT06037811RecruitingPhase 2
Adalimumab for Immunotherapy-Related Arthritis
This study tests if a medicine called adalimumab (a type of TNF blocker) can help with new joint pain and swelling (inflammatory arthritis) caused by some immunotherapy drugs. It aims to reduce the need for high-dose steroids and improve symptoms.
London, OntarioAges 18 years+ - NCT07510191RecruitingPhase 4
Comparing two ways to treat Crohn's disease if TNFi isn't working well
This trial tests if adding a low dose of a newer pill (upadacitinib) to your current TNF inhibitor (TNFi) works better than increasing the dose of your TNFi alone. It is for people with Crohn's disease who have had some improvement on their TNFi but still have active disease.
Guangzhou, GuangdongAges 18–65 - NCT06996652RecruitingPhase 2
Study of adalimumab to delay Parkinson's symptoms in sleep disorder
This trial tests whether adalimumab, an immune system drug, helps people with REM sleep behavior disorder (a condition that may warn of Parkinson's disease) stay healthy longer. Participants will receive injections of the drug or a placebo to see if it prevents Parkinson's-related brain problems.
Los Angeles, CaliforniaAges 50–80 - NCT04725422Recruiting
Registry for children with nonbacterial bone inflammation
This study collects medical information (and imaging results) from children and teens with nonbacterial bone inflammation. It may help doctors better understand how this condition looks on scans and how it’s diagnosed, especially to rule out infection or cancer.
Seattle, WashingtonAges Up to 21 years - NCT03414502RecruitingPhase 3
Predictors of Response to DMARDs in Rheumatoid Arthritis
This trial studies rheumatoid arthritis (RA) patients starting or adjusting DMARD medicines and looks for signs that predict who responds best. It may help doctors choose more effective treatment sooner.
Omaha, NebraskaAges 19 years+ - NCT03917303RecruitingPhase 4
Check-in app for people with newly diagnosed Crohn’s disease
This Phase 4 study tests whether using the myIBDcoach smartphone app helps people with Crohn’s disease manage their care. It’s for people who are newly diagnosed or having a flare and have not used biologic medicines before.
MaastrichtAges 18–70 - NCT05040464RecruitingPhase 3
Azathioprine or methotrexate added to adalimumab for Crohn’s
This trial compares two medicine options (azathioprine vs methotrexate) when added to adalimumab to treat active Crohn’s disease. It may help determine which add-on works better for people whose Crohn’s is still active despite standard treatments or who can’t take them.
AmiensAges 18 years+ - NCT05313620RecruitingPhase 4
Tofacitinib effect on clotting tests in ulcerative colitis
This study looks at how tofacitinib (and related medicines) may affect clotting and blood-platelet function, and whether this could relate to blood clot risk. It includes detailed blood and stool/colonoscopy-related testing in adults with ulcerative colitis and in some people without it.
Madrid, MadridAges 18 years+ - NCT05503875Recruiting
Study uses psoriasis “immune patterns” to guide treatment
This study looks at immune system differences in people with moderate-to-severe psoriasis. It aims to help guide more precise (targeted) treatment choices and may improve how well treatment works for you.
Hangzhou, ZhejiangAges 18–75 - NCT05590455RecruitingPhase 2
Testing a TNF-blocking drug to reduce death in HIV and TB meningitis
This Phase 2 trial studies whether a TNF-blocking medicine can lower the risk of death in people with HIV who also have TB meningitis. You would receive standard TB meningitis treatment plus the study drug, if you meet the criteria.
Rio de JaneiroAges 18 years+ - NCT05626348RecruitingPhase 4
Test immune-modulator treatments for rheumatoid arthritis with knee trouble
This Phase 4 trial studies whether immune-modulator medicines improve symptoms and function in people with rheumatoid arthritis who have knee problems. It may also compare responses in osteoarthritis and healthy volunteers, depending on the group you fit.
Jinan, ShandongAges 18–80 - NCT05928039RecruitingPhase 4
Choosing the best first biologic for Crohn’s in the ileum
This Phase 4 trial tests which type of biologic medicine works best as the first treatment for people with moderate-to-severe Crohn’s that mainly affects the ileum. It may help you and your care team choose a more effective first option, based on which strategy leads to better control of symptoms and intestinal inflammation.
Calgary, AlbertaAges 18 years+ - NCT06062875RecruitingPhase 2
Testing a drug for enlarged prostate symptoms
This trial tests whether a drug called adalimumab (a TNF blocker) can improve symptoms of an enlarged prostate. It is for men aged 45-80 with a large prostate and bothersome urinary symptoms who have not used this type of medication before.
Glenview, IllinoisAges 45–80 - NCT07694674Recruiting
Comparing Biologic Drugs to Prevent Crohn's Return After Surgery
This trial compares different biologic medications to see which best prevents Crohn's disease from coming back after intestinal surgery. It may help you if you have had surgery for Crohn's and are starting a biologic drug soon after.
Shanghai, Shanghai MunicipalityAges 18–85
What Adalimumab is being studied for
Conditions with recruiting Adalimumab studies.
Common questions
- Are there clinical trials studying Adalimumab?
- Yes. Clin2 currently lists 34 recruiting studies that include Adalimumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Adalimumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Adalimumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Adalimumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.